Phase III Trials In Wet AMD Will Expand Market Reach

EyePoint Pharmaceuticals’ consensus price target remained unchanged at $34.42, as strong Phase 2 data and operational improvements offset in-line clinical progress in the development of Duravyu. Analyst Commentary Completion of enrollment in the second Phase 3 LUCIA study for Duravyu.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has increased future PE multiple from 131.7x to 192.9x and decreased shares outstanding growth rate from 0.3% to 0.1%.